By Hongjiang Li | Jan 25, 2019 | 10:16 PM GMT Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China.
US pharma company Pfizer has launched China's first pay-for-performance insurance product, with breast cancer drug Ibrance palbociclib, in partnership with PICC Health Insurance and Shanghai MediTrust Health. The programme is being rolled out in 34 cities, and is available to a maximum of 500 patients with no previous first-line endocrine therapy treatment. Pfizer said those experiencing disease progression or metastasis within the first 126 days of beginning Ibrance treatment, or in combination with an aromatase inhibitor, will be reimbursed with up to 33.5% of the cost.